8-K Announcements
6Material company update
Mar 5, 2026·SEC
Material company update
Feb 13, 2026·SEC
Material company update
Feb 11, 2026·SEC
Moderna, Inc.(MRNA)Earnings, Financials & Key Ratios
MRNA•NASDAQ
Price updated Jun 19, 2026
AboutModerna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$1.94B-39.2%
- EBITDA-$2.86B+23.9%
- Net Income-$2.82B+20.8%
- EPS (Diluted)-7.26+21.7%
- Gross Margin55.35%+2.1%
- EBITDA Margin-147.07%-25.3%
- Operating Margin-158.13%-28.2%
- Net Margin-145.16%-30.4%
- ROE-28.87%-0.3%
MRNA Key Insights
Moderna, Inc. (MRNA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 94 (top 6%)
- ✓Strong 5Y sales CAGR of 19.3%
✗Weaknesses
- ✗Profits declining 30.4% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MRNA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MRNA Price & Volume
Moderna, Inc. (MRNA) stock price & volume — 10-year historical chart
Loading chart...
MRNA Growth Metrics
Moderna, Inc. (MRNA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years19.33%
3 Years-53.13%
TTM-29.12%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM4.86%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM6.62%
Return on Capital
10 Years-3.18%
5 Years23.14%
3 Years-26.59%
Last Year-27.59%
MRNA Recent Earnings
Moderna, Inc. (MRNA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
May 1, 2026Metric
Actual
Est
EPS
$3.40+23.6%
$4.45
Rev
$389M+64.6%
$236M
Q1 2026
Feb 13, 2026Metric
Actual
Est
EPS
$2.11+16.9%
$2.54
Rev
$678M+6.7%
$635M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.51+72.7%
$1.87
Rev
$1.0B+10.3%
$921M
Q3 2025
Aug 1, 2025Metric
Actual
Est
EPS
$2.13+28.8%
$2.99
Rev
$142M-84.1%
$893M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 1, 2026 | $3.40vs $4.45+23.6% | $389Mvs $236M+64.6% |
| Q1 2026 | Feb 13, 2026 | $2.11vs $2.54+16.9% | $678Mvs $635M+6.7% |
| Q4 2025 | Nov 6, 2025 | $0.51vs $1.87+72.7% | $1.0Bvs $921M+10.3% |
| Q3 2025 | Aug 1, 2025 | $2.13vs $2.99+28.8% | $142Mvs $893M-84.1% |
Based on last 12 quarters of dataView full earnings history →
MRNA Peer Comparison
Moderna, Inc. (MRNA) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BNTX | 22.98B | 90.89 | -17.51 | 0.2% | -39.6% | -6.03% | 0.01 | |
 NVAX | 1.5B | 9.13 | 3.59 | 64.69% | -14.73% | |||
 CVAC | 1.05B | 4.66 | 6.47 | 8.96% | 37.93% | 33.02% | 0.06 | |
 PFE | 143.46B | 25.22 | 18.54 | -1.65% | 11.83% | 8.34% | 0.78 | |
 JNJ | 550.4B | 228.39 | 39.45 | 4.3% | 27.26% | 31.69% | 0.51 | |
 AZN | 271.19B | 174.93 | 26.75 | 8.63% | 17.19% | 22.24% | 0.61 | |
 GILD | 153.66B | 123.76 | 18.25 | 2.39% | 30.99% | 42.33% | 1.09 | |
 REGN | 63.37B | 609.94 | 14.70 | 0.99% | 29.65% | 14.32% | 0.09 |
Compare MRNA vs Peers
Moderna, Inc. (MRNA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MRNA Income Statement
Moderna, Inc. (MRNA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 205.82M | 135.07M | 60.21M | 803.39M | 17.74B | 18.88B | 6.85B | 3.2B | 1.94B | 2.23B |
Revenue Growth % | 89.88% | -34.38% | -55.42% | 1234.34% | 2107.63% | 6.42% | -63.72% | -53.29% | -39.23% | -29.12% |
Cost of Goods Sold | 20.54M | 24.86M | 31.02M | 39.18M | 2.62B | 5.42B | 4.69B | 1.46B | 868M | 2.53B |
COGS % of Revenue | 9.98% | 18.41% | 51.52% | 4.88% | 14.76% | 28.69% | 68.53% | 45.76% | 44.65% | - |
Gross Profit | 185.29M▲ 0% | 110.21M▼ 40.5% | 29.19M▼ 73.5% | 764.21M▲ 2518.2% | 15.12B▲ 1878.4% | 13.46B▼ 11.0% | 2.15B▼ 84.0% | 1.74B▼ 19.5% | 1.08B▼ 38.0% | -309M▲ 0% |
Gross Margin % | 90.02% | 81.59% | 48.48% | 95.12% | 85.24% | 71.31% | 31.47% | 54.24% | 55.35% | -13.89% |
Gross Profit Growth % | 98.63% | -40.52% | -73.52% | 2518.24% | 1878.38% | -10.98% | -83.99% | -19.49% | -37.98% | - |
Operating Expenses | 454.64M | 94.25M | 574.91M | 1.53B | 1.82B | 4.04B | 6.39B | 5.68B | 4.15B | 3.1B |
OpEx % of Revenue | 220.89% | 69.78% | 954.85% | 190.11% | 10.28% | 21.4% | 93.37% | 177.56% | 213.48% | - |
Selling, General & Admin | 64.72M | 94.25M | 109.62M | 188.27M | 567M | 1.13B | 1.55B | 1.17B | 1.02B | 979M |
SG&A % of Revenue | 31.45% | 69.78% | 182.07% | 23.43% | 3.2% | 6% | 22.62% | 36.7% | 52.37% | - |
Research & Development | 410.46M | 454.08M | 496.31M | 1.37B | 1.99B | 3.29B | 4.84B | 4.54B | 3.13B | 2.92B |
R&D % of Revenue | 199.42% | 336.19% | 824.31% | 170.57% | 11.23% | 17.46% | 70.75% | 142.01% | 161.11% | - |
Other Operating Expenses | -20.54M | -454.08M | -31.02M | -31.25M | -735M | -388M | 0 | -37M | 0 | -1000K |
Operating Income | -269.36M▲ 0% | -468.87M▼ 74.1% | -545.72M▼ 16.4% | -763.14M▼ 39.8% | 13.3B▲ 1842.3% | 9.42B▼ 29.2% | -4.24B▼ 145.0% | -3.94B▲ 6.9% | -3.07B▲ 22.1% | -3.41B▲ 0% |
Operating Margin % | -130.87% | -347.13% | -906.38% | -94.99% | 74.97% | 49.91% | -61.9% | -123.32% | -158.13% | -153.35% |
Operating Income Growth % | -20.37% | -74.07% | -16.39% | -39.84% | 1842.27% | -29.15% | -145% | 6.94% | 22.08% | - |
EBITDA | -248.82M | -444M | -514.7M | -731.89M | 13.53B | 9.77B | -3.62B | -3.76B | -2.86B | -3.24B |
EBITDA Margin % | -120.89% | -328.73% | -854.85% | -91.1% | 76.27% | 51.75% | -52.83% | -117.41% | -147.07% | -145.44% |
EBITDA Growth % | -19.25% | -78.44% | -15.92% | -42.2% | 1948.36% | -27.79% | -137.04% | -3.81% | 23.88% | 8.51% |
D&A (Non-Cash Add-back) | 20.54M | 24.86M | 31.02M | 31.25M | 232M | 348M | 621M | 189M | 215M | 176M |
EBIT | -255.86M | -436.91M | -508.1M | -734.63M | 13.3B | 9.42B | -3.9B | -3.58B | -2.77B | -1.8B |
Net Interest Income | 15.1M | 23.93M | 31.92M | 14.83M | 0 | 171M | 383M | 401M | 314M | 223M |
Interest Income | 15.23M | 27.02M | 38.53M | 24.71M | 18M | 200M | 421M | 425M | 314M | 296M |
Interest Expense | 132K | 3.1M | 6.61M | 9.89M | 18M | 29M | 38M | 24M | 0 | 1M |
Other Income/Expense | 13.36M | 28.86M | 31M | 18.63M | -11M | 155M | 297M | 338M | 306M | 274M |
Pretax Income | -256M▲ 0% | -440.01M▼ 71.9% | -514.72M▼ 17.0% | -744.51M▼ 44.6% | 13.29B▲ 1884.4% | 9.57B▼ 27.9% | -3.94B▼ 141.2% | -3.61B▲ 8.5% | -2.77B▲ 23.3% | -3.14B▲ 0% |
Pretax Margin % | -124.38% | -325.77% | -854.88% | -92.67% | 74.9% | 50.73% | -57.56% | -112.75% | -142.39% | -141.03% |
Income Tax | -80K | 326K | -695K | 2.55M | 1.08B | 1.21B | 772M | -46M | 54M | 56M |
Effective Tax Rate % | 0.03% | -0.07% | 0.14% | -0.34% | 8.15% | 12.67% | -19.58% | 1.28% | -1.95% | -1.78% |
Net Income | -255.92M▲ 0% | -384.73M▼ 50.3% | -514.02M▼ 33.6% | -747.06M▼ 45.3% | 12.2B▲ 1733.3% | 8.36B▼ 31.5% | -4.71B▼ 156.4% | -3.56B▲ 24.5% | -2.82B▲ 20.8% | -3.19B▲ 0% |
Net Margin % | -124.34% | -284.84% | -853.73% | -92.99% | 68.8% | 44.3% | -68.84% | -111.32% | -145.16% | -143.55% |
Net Income Growth % | -18.36% | -50.34% | -33.6% | -45.34% | 1733.33% | -31.47% | -156.37% | 24.46% | 20.75% | 4.86% |
Net Income (Continuing) | -255.92M | -384.73M | -514.02M | -747.06M | 12.2B | 8.36B | -4.71B | -3.56B | -2.82B | -3.19B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.72▲ 0% | -1.17▼ 62.5% | -1.55▼ 32.5% | -1.96▼ 26.5% | 28.29▲ 1543.4% | 20.10▼ 29.0% | -12.34▼ 161.4% | -9.27▲ 24.9% | -7.26▲ 21.7% | -8.09▲ 0% |
EPS Growth % | 81% | -62.5% | -32.48% | -26.45% | 1543.37% | -28.95% | -161.39% | 24.88% | 21.68% | 6.62% |
EPS (Basic) | -0.72 | -1.17 | -1.55 | -1.96 | 30.31 | 21.26 | -12.34 | -9.27 | -7.26 | - |
Diluted Shares Outstanding | 376M | 328.8M | 330.8M | 381.33M | 431M | 416M | 382M | 384M | 389M | 395M |
Basic Shares Outstanding | 376M | 328.8M | 330.8M | 381.33M | 403M | 394M | 382M | 384M | 389M | 395M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
MRNA Balance Sheet
Moderna, Inc. (MRNA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 783.22M | 1.56B | 1.13B | 6.3B | 16.07B | 13.43B | 10.32B | 8.1B | 6.54B | 5.77B |
Cash & Short-Term Investments | 756.03M | 1.52B | 1.1B | 4.61B | 10.73B | 9.9B | 8.6B | 7.03B | 5.8B | 1.91B |
Cash Only | 134.86M | 658.36M | 235.88M | 2.62B | 6.85B | 3.21B | 2.91B | 1.93B | 2.6B | 1.91B |
Short-Term Investments | 621.17M | 863.06M | 867.12M | 1.98B | 3.88B | 6.7B | 5.7B | 5.1B | 3.2B | 0 |
Accounts Receivable | 18.4M | 30.58M | 16.3M | 1.41B | 3.32B | 1.69B | 1.08B | 592M | 184M | 71M |
Days Sales Outstanding | 32.64 | 82.65 | 98.8 | 639.69 | 68.39 | 32.58 | 57.62 | 67.55 | 34.55 | 86.37 |
Inventory | 0 | 0 | 0 | 47M | 1.44B | 949M | 202M | 117M | 153M | 146M |
Days Inventory Outstanding | - | - | - | 437.81 | 200.98 | 63.96 | 15.71 | 29.17 | 64.34 | 31.36 |
Other Current Assets | 951K | 595K | 1.03M | 11M | 26M | 44M | 88M | 58M | 408M | 3.65B |
Total Non-Current Assets | 301.27M | 399.14M | 460.62M | 1.04B | 8.6B | 12.43B | 8.1B | 6.04B | 5.79B | 5.72B |
Property, Plant & Equipment | 139.03M | 211.98M | 287.91M | 387M | 1.38B | 2.14B | 2.66B | 2.96B | 2.85B | 2.79B |
Fixed Asset Turnover | 1.48x | 0.64x | 0.21x | 2.08x | 12.82x | 8.82x | 2.58x | 1.08x | 0.68x | 0.78x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 52M | 52M | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 44M | 40M | 0 | 0 |
Long-Term Investments | 145.85M | 172.99M | 159.99M | 639M | 6.84B | 8.36B | 4.74B | 2.51B | 2.34B | 9.22B |
Other Non-Current Assets | 16.38M | 14.18M | 12.72M | 13M | 46M | 946M | 523M | 407M | 605M | 675M |
Total Assets | 1.08B▲ 0% | 1.96B▲ 80.9% | 1.59B▼ 19.0% | 7.34B▲ 361.6% | 24.67B▲ 236.2% | 25.86B▲ 4.8% | 18.43B▼ 28.7% | 14.14B▼ 23.2% | 12.34B▼ 12.8% | 11.49B▲ 0% |
Asset Turnover | 0.19x | 0.07x | 0.04x | 0.11x | 0.72x | 0.73x | 0.37x | 0.23x | 0.16x | 0.19x |
Asset Growth % | -23.47% | 80.93% | -19% | 361.61% | 236.23% | 4.82% | -28.74% | -23.25% | -12.76% | -68.94% |
Total Current Liabilities | 191.46M | 222.8M | 143.12M | 4.39B | 9.13B | 4.92B | 3.02B | 2.21B | 1.99B | 2.4B |
Accounts Payable | 20.73M | 31.21M | 7.09M | 18M | 302M | 487M | 520M | 405M | 317M | 161M |
Days Payables Outstanding | 368.34 | 458.2 | 83.42 | 167.67 | 42.12 | 32.82 | 40.44 | 100.97 | 133.3 | 33.13 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 96.74M | 109.06M | 63.31M | 3.87B | 6.25B | 2.04B | 568M | 153M | 99M | 582M |
Other Current Liabilities | 19.5M | 26.87M | 32.49M | 99M | 140M | 243M | 842M | 863M | 1.57B | 2.29B |
Current Ratio | 4.09x | 7.02x | 7.89x | 1.43x | 1.76x | 2.73x | 3.42x | 3.67x | 3.29x | 2.41x |
Quick Ratio | 4.09x | 7.02x | 7.89x | 1.42x | 1.60x | 2.54x | 3.36x | 3.62x | 3.22x | 2.35x |
Cash Conversion Cycle | - | - | - | 909.82 | 227.25 | 63.72 | 32.88 | -4.26 | -34.42 | 84.61 |
Total Non-Current Liabilities | 267.73M | 209.1M | 271.5M | 387M | 1.4B | 1.81B | 1.56B | 1.03B | 1.7B | 1.69B |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.24B | 1.25B |
Capital Lease Obligations | 15.69M | 33.49M | 132.36M | 207M | 705M | 1B | 1.22B | 710M | 673M | 2.06B |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 239M |
Other Non-Current Liabilities | 9.12M | 10.26M | 138K | 3M | 76M | 135M | 256M | 267M | -368M | 437M |
Total Liabilities | 459.19M | 431.91M | 414.61M | 4.78B | 10.52B | 6.74B | 4.57B | 3.24B | 3.69B | 4.08B |
Total Debt | 15.69M | 33.49M | 132.36M | 237M | 916M | 1.2B | 1.24B | 747M | 1.92B | 1.25B |
Net Debt | -119.17M | -624.88M | -103.51M | -2.39B | -5.93B | -2B | -1.66B | -1.18B | -679M | -660M |
Debt / Equity | 0.03x | 0.02x | 0.11x | 0.09x | 0.06x | 0.06x | 0.09x | 0.07x | 0.22x | 0.17x |
Debt / EBITDA | - | - | - | - | 0.07x | 0.12x | - | - | - | -0.39x |
Net Debt / EBITDA | - | - | - | - | -0.44x | -0.21x | - | - | - | 0.20x |
Interest Coverage | -1938.36x | -141.12x | -76.85x | -74.31x | 738.67x | 324.83x | -102.74x | -149.29x | - | -1803.00x |
Total Equity | 625.3M▲ 0% | 1.53B▲ 144.7% | 1.17B▼ 23.2% | 2.56B▲ 118.0% | 14.14B▲ 452.3% | 19.12B▲ 35.2% | 13.85B▼ 27.6% | 10.9B▼ 21.3% | 8.65B▼ 20.6% | 7.41B▲ 0% |
Equity Growth % | -25.72% | 144.72% | -23.23% | 117.99% | 452.32% | 35.19% | -27.55% | -21.32% | -20.65% | -88.58% |
Book Value per Share | 1.66 | 4.65 | 3.55 | 6.72 | 32.82 | 45.97 | 36.27 | 28.39 | 22.24 | 18.75 |
Total Shareholders' Equity | 625.3M | 1.53B | 1.17B | 2.56B | 14.14B | 19.12B | 13.85B | 10.9B | 8.65B | 7.41B |
Common Stock | 6K | 33K | 34K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -621.89M | -1.01B | -1.5B | -2.24B | 9.96B | 18.32B | 13.61B | 10.04B | 7.22B | 5.88B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -1.16M | -1.32M | 1.8M | 3M | -24M | -370M | -123M | -10M | 45M | 25M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MRNA Cash Flow Statement
Moderna, Inc. (MRNA) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -331.48M | -330.87M | -458.97M | 2.03B | 13.62B | 4.98B | -3.12B | -3B | -1.87B | -1.45B |
Operating CF Margin % | -161.05% | -244.96% | -762.29% | 252.3% | 76.79% | 26.39% | -45.53% | -93.9% | -96.35% | - |
Operating CF Growth % | -596.72% | 0.19% | -38.72% | 541.64% | 571.94% | -63.43% | -162.6% | 3.66% | 37.65% | 128.3% |
Net Income | -255.92M | -384.73M | -514.02M | -747.06M | 12.2B | 8.36B | -4.71B | -3.56B | -2.82B | -3.19B |
Depreciation & Amortization | 20.54M | 24.86M | 31.02M | 93M | 232M | 348M | 621M | 189M | 215M | 116M |
Stock-Based Compensation | 40.05M | 72.56M | 81.12M | 93M | 142M | 226M | 305M | 429M | 483M | 234M |
Deferred Taxes | 0 | 0 | 0 | 10.42M | -318M | -559M | 828M | 0 | 0 | 0 |
Other Non-Cash Items | 1.09M | -975K | -3.43M | 558K | 54M | 59M | -19M | 17M | -3M | 934M |
Working Capital Changes | -137.25M | -42.58M | -53.66M | 2.58B | 1.31B | -3.46B | -139M | -78M | 254M | 465M |
Change in Receivables | 106K | 832K | 7.22M | -1.39B | -1.78B | 1.79B | 493M | 534M | 156M | -10M |
Change in Inventory | 34.8M | 4.41M | 7.2M | -46.53M | -1.39B | 492M | 747M | 83M | -34M | -20M |
Change in Payables | -12.77M | 15.02M | -23.96M | 11.88M | 204M | 240M | 13M | -69M | -92M | -56M |
Cash from Investing | 416.1M | -372.47M | -14.95M | -1.67B | -8.52B | -5.18B | 4.21B | 1.95B | 1.95B | 1.14B |
Capital Expenditures | -58.4M | -105.77M | -31.55M | -67.45M | -284M | -400M | -707M | -1.05B | -192M | -137M |
CapEx % of Revenue | 28.37% | 78.31% | 52.41% | 8.4% | 1.6% | 2.12% | 10.32% | 32.85% | 9.88% | 6.16% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | -85M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -1.27M | 622K | 0 | 0 | -30M | -40M | 0 | 0 | -10M | 0 |
Cash from Financing | 168K | 1.23B | 51.12M | 2.03B | -873M | -3.45B | -1.38B | 56M | 593M | 585M |
Debt Issued (Net) | 1.44M | 9.46M | 1M | -6M | -140M | -184M | -270M | -10M | 539M | 537M |
Equity Issued (Net) | 212K | 1.22B | 50.15M | 2.04B | -733M | -3.26B | -1.11B | 66M | 35M | 32M |
Dividends Paid | -1.48M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -8.18M | 2.89M | 0 | -857M | -3.33B | -1.15B | 0 | 0 | 0 |
Other Financing | 0 | 0 | -29K | 193K | 0 | 0 | 0 | 0 | 19M | 16M |
Net Change in Cash | 84.78M▲ 0% | 523.5M▲ 517.5% | -422.79M▼ 180.8% | 2.39B▲ 664.9% | 4.22B▲ 76.9% | -3.64B▼ 186.2% | -289M▲ 92.1% | -999M▼ 245.7% | 668M▲ 166.9% | 282M▲ 0% |
Free Cash Flow | -389.88M▲ 0% | -436.63M▼ 12.0% | -490.52M▼ 12.3% | 1.96B▲ 499.5% | 13.34B▲ 580.6% | 4.58B▼ 65.6% | -3.83B▼ 183.5% | -4.05B▼ 6.0% | -2.06B▲ 49.1% | -1.58B▲ 0% |
FCF Margin % | -189.43% | -323.27% | -814.7% | 243.91% | 75.19% | 24.27% | -55.86% | -126.76% | -106.22% | -71.1% |
FCF Growth % | -1260.72% | -11.99% | -12.34% | 499.48% | 580.57% | -65.65% | -183.5% | -6.01% | 49.08% | 60.78% |
FCF per Share | -1.04 | -1.33 | -1.48 | 5.14 | 30.94 | 11.01 | -10.01 | -10.56 | -5.31 | -4.01 |
FCF Conversion (FCF/Net Income) | 1.30x | 0.86x | 0.89x | -2.71x | 1.12x | 0.60x | 0.66x | 0.84x | 0.66x | 0.50x |
Interest Paid | 0 | 3M | 0 | 9M | 14M | 25M | 39M | 24M | 0 | 0 |
Taxes Paid | 398K | 294K | 0 | 1M | 480M | 2.73B | 0 | 197M | 0 | 0 |
MRNA Key Ratios
Moderna, Inc. (MRNA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -34.89% | -35.7% | -38% | -39.99% | 146.08% | 50.27% | -28.59% | -28.77% | -28.87% | -36.73% |
Return on Invested Capital (ROIC) | -30.83% | -49.83% | -41.41% | -91.92% | 237.8% | 55.78% | -21.7% | -27.01% | -26.06% | -30.86% |
Gross Margin | 90.02% | 81.59% | 48.48% | 95.12% | 85.24% | 71.31% | 31.47% | 54.24% | 55.35% | -13.89% |
Net Margin | -124.34% | -284.84% | -853.73% | -92.99% | 68.8% | 44.3% | -68.84% | -111.32% | -145.16% | -143.55% |
Debt / Equity | 0.03x | 0.02x | 0.11x | 0.09x | 0.06x | 0.06x | 0.09x | 0.07x | 0.22x | 0.17x |
Interest Coverage | -1938.36x | -141.12x | -76.85x | -74.31x | 738.67x | 324.83x | -102.74x | -149.29x | - | -1803.00x |
FCF Conversion | 1.30x | 0.86x | 0.89x | -2.71x | 1.12x | 0.60x | 0.66x | 0.84x | 0.66x | 0.50x |
Revenue Growth | 89.88% | -34.38% | -55.42% | 1234.34% | 2107.63% | 6.42% | -63.72% | -53.29% | -39.23% | -29.12% |
Related:MRNA Dividend History·MRNA Revenue History·MRNA Price History·MRNA P/E History·MRNA Financial Ratios·MRNA Institutional Holders
MRNA SEC Filings & Documents
Moderna, Inc. (MRNA) SEC filings — annual & quarterly reports (10-K, 10-Q)
MRNA Frequently Asked Questions
Moderna, Inc. (MRNA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Moderna, Inc. (MRNA) reported $2.23B in revenue for fiscal year 2025. This represents a 1953% increase from $108.4M in 2016.
Moderna, Inc. (MRNA) saw revenue decline by 39.2% over the past year.
Moderna, Inc. (MRNA) reported a net loss of $3.19B for fiscal year 2025.
Dividend & Returns
Moderna, Inc. (MRNA) has a return on equity (ROE) of -28.9%. Negative ROE indicates the company is unprofitable.
Moderna, Inc. (MRNA) had negative free cash flow of $1.58B in fiscal year 2025, likely due to heavy capital investments.